Primary Objective:~-To evaluate Safety of the combination of azacitidine, venetoclax and allogeneic NK cells~Secondary Objective:~To estimate overall response rate (ORR)~To estimate rate of CR/CRi by 4 cycles of therapy~To estimate rate of MRD negative by 6 cycles~To estimate overall survival (OS)~To estimate relapse-free survival (RFS)~Exploratory Objectives:~To estimate rate of CRc MRD negative at any time~To estimate event-free survival (EFS)~To estimate duration of response (DOR)~To estimate median time to blood count recovery~To estimate median time to first response~To estimate median time to negative MRD~To evaluate persistence of NK cells in peripheral blood~To explore biomarker of response and resistance~Using propensity-score matching analysis (per post-hoc plan) to explore the difference in response, survival adverse events in contemporary historical control population treated with HMA-VEN
To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.